We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > rilpivirine

News List

US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment expresspharma
January 22, 2021
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
First long-acting HIV treatment approved in Europe europeanpharmaceuticalreview
January 05, 2021
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
Cabenuva (cabotegravir and rilpivirine) granted approval by Health Canada europeanpharmaceuticalreview
March 24, 2020
The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) has been granted by Health Canada, in conjunction with use of Vocabria.
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
July 13, 2018
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
July 12, 2018
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.